BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37239866)

  • 1. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.
    Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
    Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
    Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
    Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
    Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
    Hussein NA; Mohamed SN; Ahmed MA
    Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
    Yu Z; Qin S; Wang H
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer.
    Wang W; Liang M; Ma G; Li L; Zhou W; Xia T; Xie H; Wang S
    Neoplasma; 2017; 64(4):611-618. PubMed ID: 28485169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
    Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
    Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Cell-Free DNA Is a Potential Biomarker for Diagnosis of Calcific Aortic Valve Disease.
    Ma W; Zhang W; Liu H; Qian B; Lai R; Yao Z; Wang Y; Yan Y; Yuan Z
    Cardiology; 2024; 149(2):155-162. PubMed ID: 37899036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.
    Benati M; Montagnana M; Danese E; Mazzon M; Paviati E; Garzon S; Laganà AS; Casarin J; Giudici S; Raffaelli R; Ghezzi F; Franchi M; Lippi G
    Pathol Oncol Res; 2020 Oct; 26(4):2281-2289. PubMed ID: 32462419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.
    Murillo Carrasco A; Acosta O; Ponce J; Cotrina J; Aguilar A; Araujo J; Rebaza P; Pinto JA; Fujita R; Buleje J
    J Clin Lab Anal; 2021 Apr; 35(4):e23720. PubMed ID: 33522650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
    Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
    Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
    Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
    Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of circulating cell-free DNA and its integrity as a biomarker for diagnosis of breast cancer using ALU (247/115) bP sequences.
    Abd El Hafeez HA; Abd El Rahman MZ; Kamel TM; Rezk KM; Mohamed FM; Abdel-Hameed ZA
    Egypt J Immunol; 2023 Jul; 30(3):44-55. PubMed ID: 37439529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
    Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
    Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer.
    Chen X; Lin Y; Jiang Z; Li Y; Zhang Y; Wang Y; Yu F; Guo W; Chen L; Chen M; Zhang W; Wang C; Fu F
    Breast; 2022 Apr; 62():114-122. PubMed ID: 35158152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence.
    Cheng J; Cuk K; Heil J; Golatta M; Schott S; Sohn C; Schneeweiss A; Burwinkel B; Surowy H
    Oncotarget; 2017 Aug; 8(33):54537-54547. PubMed ID: 28903362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.